Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Camms Investigators"'
Autor:
Antonio Bertolotto, Mark S. Freedman, Isabel Firmino, Darren P Baker, Alan Jacobs, Karthinathan Thangavelu, Tjalf Ziemssen, Aaron Boster, Nadia Daizadeh, Dana Horakova, Camms Investigators, Steven J. Cavalier, David Margolin, Elizabeth M. Poole
Publikováno v:
Multiple Sclerosis Journal-Experimental, Translational and Clinical
Background Few data exist concerning conversion to secondary progressive MS in patients treated with disease-modifying therapies. Objective Determine the proportion of alemtuzumab-treated patients converting from relapsing-remitting to secondary prog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa925ec8d40e90ce675dbd946adcd10f
http://europepmc.org/articles/PMC7750777
http://europepmc.org/articles/PMC7750777
Autor:
Alasdair Coles, Madalina C Chirieac, D Alastair S Compston, Karthinathan Thangavelu, Sven Schippling, Hans-Peter Hartung, Richard J. Hogan, Eva Havrdova, Darlene Jody, Gavin Giovannoni, David Margolin, Anthony Traboulsee, Michael Panzara, Edward Fox, Krzysztof Selmaj, Jeffrey A. Cohen, Camms Investigators, Panos Xenopoulos, Douglas L. Arnold, Care-Ms
Publikováno v:
Neurology
Neurology, 89(11), 1117-1126. LIPPINCOTT WILLIAMS & WILKINS
Neurology, 89(11), 1117-1126. LIPPINCOTT WILLIAMS & WILKINS
Objective:To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy.Methods:In the 2-year Comparison of Alemtuzumab and Rebif Efficacy in Multiple Scl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::039f56aae82a7071a0c5fbb5d436ea58
https://pubmed.ncbi.nlm.nih.gov/30224508
https://pubmed.ncbi.nlm.nih.gov/30224508
Autor:
Camms Investigators, Comi Giancarlo, Bass Ann, Boster Aaron, Berkovich Regina, Singer Barry, Fernández Óscar, Kim Ho Jin, Sharrack Basil, Limmroth Volker
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 89:A23.2-A23
Efficacy of alemtuzumab retreatment (course [C] 3) after the initial 2 courses were evaluated (CARE-MS II, NCT00548405; extension, NCT00930553). Patients received alemtuzumab retreatment (12 mg/day, 3 consecutive days;≥12 months apart) as needed fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ef83daf78058ac852dac426a36b5566
https://doi.org/10.1136/jnnp-2018-abn.82
https://doi.org/10.1136/jnnp-2018-abn.82
Autor:
David Margolin, Camms Investigators, Alasdair Coles, D Alastair S Compston, Kim Norris, Krzysztof Selmaj, P K Tandon, Susan Moran, Stephen Lake
Publikováno v:
New England Journal of Medicine. 359:1786-1801
Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis.In this phase 2, randomized, blinded trial involving previously untreated, early, relapsing-remitt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2367f07b0762f23154808ad03e0b52ca
https://doi.org/10.1056/nejmoa0802670
https://doi.org/10.1056/nejmoa0802670